OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections
03 juin 2020 06h00 HE
|
OpGen, Inc.
Collaboration with NYS Department of Health’s Wadsworth Center continues for second year term Project to utilize OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health...
U.S. Patent Allowed Covering Acuitas Lighthouse® Software
23 oct. 2019 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed a key OpGen patent...
OpGen Presents Preliminary Acuitas® AMR Gene Panel Data for Detecting Urinary Tract Infections
07 oct. 2019 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) today announced the presentation of preliminary data at IDWeek 2019 for the Company’s Acuitas® AMR Gene Panel and...
OpGen Provides update on Curetis Group’s R&D Collaboration
18 sept. 2019 07h30 HE
|
OpGen, Inc.
Curetis R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbCollaborator to fund R&D and obtains option to license ARESdb and ARES Technology...
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
04 sept. 2019 06h55 HE
|
OpGen, Inc.
Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for molecular microbiologyCombined company to be headquartered in Gaithersburg, MD,...
OpGen’s Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy
27 juin 2019 07h30 HE
|
OpGen, Inc.
Collaborator data demonstrating OpGen’s rapid prediction of antibiotic resistance and detection of uropathogens presented at ASM Microbe 2019 GAITHERSBURG, Md., June 27, 2019 (GLOBE NEWSWIRE) --...
OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection
13 juin 2019 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., June 13, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that data from its Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software will be presented at ASM...
Panel identifies interventions and preferred measures to advance antimicrobial stewardship
21 mai 2019 13h00 HE
|
The Joint Commission
OAKBROOK TERRACE, Ill., May 21, 2019 (GLOBE NEWSWIRE) -- An estimated 2 million people become infected with bacteria that are resistant to antibiotics each year in the United States. The concept of...
OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance
14 mai 2019 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that it has filed its 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance...
OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship
25 mars 2019 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., March 25, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today it will host an event with ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s...